For Immediate Release
July 2007

Ichor Medical Systems

Fact Sheet

***The Company*:** Ichor Medical Systems, a privately held biotech company founded in 1994, is developing products to enhance the efficiency of DNA drugs and vaccines in the prevention and treatment of a wide range of diseases. Towards this end it uses a patented method of electroporation which generates a brief electrical pulse to create temporary pathways through a cell's membrane, thereby improving the uptake of various agents by up to 1,000 times compared to other methods of delivery.

Ichor's patented TriGrid™ Delivery System is the first and only integrated and fully automated electroporation system for DNA administration. With the push of a button, Ichor's TriGrid delivers DNA drugs in a carefully controlled manner for reproducible results– an outcome that is quite difficult to achieve using conventional multi-step electroporation procedures.

Ichor's TriGrid is currently being used on three continents in collaborations with some of the world's leading research organizations and medical centers in pre-clinical and clinical studies for novel treatments of cancer, HIV, hepatitis, bio-defense, and avian flu. TriGrid provides several significant advances over multi-step manual electroporation systems in which DNA is injected at a marked site and the operator implants electrodes manually in the second step. The latter process is subject to considerable patient and operator variability.

As Ichor's competitors evaluate their devices' low efficiency and inconsistent results, it is likely that they will logically move into Ichor's space and attempt to develop an integrated, automated single-step electroporation device. Throughout the development of the TriGrid, Ichor has been aware of this threat and the company remains confident that its patent portfolio will exclude its competitors from commercialization of such next generation devices.

Ichor has an excellent patent position and a far superior electroporation technology, with significant opportunities to be an enabling technology in the emerging DNA Vaccine market and a disruptive platform in the growing $40 billion therapeutic protein markets.

***Company Founder*:** Robert Bernard, President & CEO

***The Details*:** Since its inception in 1994, Ichor's dedicated team of engineers, scientists, and medical doctors have worked diligently to develop and perfect its proprietary electroporation system that would eliminate the errors and variability inherent in existing multi-step electroporation procedures. The TriGrid system offers a new level of precision and the potential to unlock the promise of DNA-based vaccines and gene therapies.

As of spring 2007, Ichor has 25 scientists, engineers and technicians working in its 6,500 square foot corporate headquarters in the Sorrento Mesa area, in the heart of San Diego's thriving biotechnology cluster.

Partnerships: Ichor is actively seeking opportunities to collaborate with leading research institutions and pharmaceutical companies around the world. The enabling power of Ichor's TriGrid Delivery System makes Ichor an attractive partner for those interested in examining the potential of new DNA drugs – or re-examining the potential of DNA drugs previously abandoned due to difficulty in reproducing results.

Ichor is presently conducting human studies evaluating a cancer vaccine with Memorial Sloan Kettering Cancer Center in New York. Current research partnerships include Aaron Diamond AIDS Research Center, the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), the Johns Hopkins Bloomberg School of Public Health, Rockefeller University, the Vaccine and Infectious Disease Organization (VIDO), Pharmexa-Epimmune, Genexine, Bayhill Therapeutics, The Scripps Research Institute, and the Pasteur Institute. These and other research and commercial entities are using TriGrid in a wide range of pre-clinical and clinical studies for cancer, viral hepatitis, multiple sclerosis, diabetes, and cardiovascular disease. The technology is also being used to develop vaccines for the prevention / treatment of HIV/AIDS, influenza, hospital acquired infections, and a number of infectious agents that are considered to be high priorities for biodefense.

For additional information, see www.ichorms.com. For additional inquiries, please contact:

Ichor Medical Systems – 858-550-2022
Dr. May de las Alas
mdelasalas@ichorms.com
Direct: 858-550-2022 x108

###